Physician profile
Jyothi Challa
NPI 1528144250
$2,458.50
in general payments reported to CMS, 2019-2025
40 companies · $97.17 in 2025
The $97.17 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $194 · 2021: $261 · 2022: $704 · 2023: $794 · 2024: $164 · 2025: $97.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,054.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $308.07 | 2021-2023 | Libtayo |
| Amgen INC. | $204.30 | 2020-2023 | Kyprolis, Nplate, Xgeva |
| Eisai INC. | $150.14 | 2019-2023 | |
| Genzyme Corporation | $148.48 | 2022 | |
| Novartis Pharmaceuticals Corporation | $126.36 | 2019-2025 | |
| Incyte Corporation | $114.04 | 2019 | |
| Genentech USA, INC. | $111.62 | 2022-2023 | Venclexta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.94 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $83.23 | 2019-2023 | Opdivo |
| Epizyme, INC. | $79.26 | 2021 | |
| Celgene Corporation | $77.46 | 2022-2023 | Pomalyst |
| Astrazeneca Pharmaceuticals LP | $66.59 | 2024 | Enhertu |
| Merck Sharp & Dohme LLC | $60.89 | 2019-2023 | Lynparza, Keytruda, Welireg |
| Gilead Sciences, INC. | $58.85 | 2021-2023 | Trodelvy |
| Tempus Ai, INC | $54.17 | 2024-2025 | Xt Cdx |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jyothi Challa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.